Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
Daxor reported strong clinician interest and new clinical validation of its BVA blood volume analysis system at the HFSA 2026 Annual Scientific Meeting. A Banner University Medical Center study found bedside exams miss fluid overload and true anemia in 38% of LVAD/artificial heart patients, which BVA unmasked, achieving a statistically significant diuresis improvement (p = 0.02). A separate 238-patient study validated BVA's ability to diagnose previously unmeasurable Plasma Volume Reserve depletion.
Key figures
- Study patients
- 238
- Diuresis p value
- 0.02
- Diagnostic accuracy
- 95%
- Missed derangements pct
- 38%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.